Freienbach, January 23, 2025 – EffRx Pharmaceuticals SA, a pharmaceutical company focused on the late-stage development and commercialization of medications for niche endocrine, metabolic and musculoskeletal disorders, is proud to announce that it has been awarded the EcoVadis Silver Medal in recognition of its outstanding sustainability management practices. This prestigious achievement places EffRx among the top 15% of companies evaluated by EcoVadis within its industry.
EcoVadis provides a global, measurable framework for companies wishing to formalize and enhance their Corporate Social Responsibility (CSR) efforts. Its assessments evaluate businesses on environmental impact, labor and human rights, ethics, and sustainable procurement. This Silver Medal underscores EffRx Pharmaceuticals’ dedication to continuous improvement in these areas and demonstrates its commitment to promoting transparency and accountability across its entire value chain.
“Being awarded the EcoVadis Silver Medal is a tremendous achievement for our company and a testament to our team’s hard work and dedication,” said Lorenzo Bosisio, CEO of EffRx Pharmaceuticals. “This award not only celebrates our current efforts but inspires us to continue improving our sustainability practices as we grow our impact in the Swiss healthcare industry”.
Corporate Social Responsibility (CSR) is a vital part of EffRx’s reputation towards all its stakeholders, including customers and employees. CSR further plays a key role in ensuring the long-term sustainability of operations by assessing and mitigating potential compliance, environmental, and social risks. As such EcoVadis Silver Medal reinforces EffRx’s commitment towards sustainable, ethical and environmentally conscious operations.
About EffRx Pharmaceuticals:
EffRx Pharmaceuticals is a commercial-stage Swiss-based pharmaceutical company focused on the late-stage development and commercialization of medications for niche endocrine, metabolic and musculoskeletal disorders. EffRx’s lead product, Binosto®, for the treatment of osteoporosis, is successfully commercialized through licensees across Europe, US, Asia and Middle East. EffRx also directly markets a portfolio of rare disease, endocrinology, and musculoskeletal treatments in Switzerland. EffRx is majority-owned by Abiogen Pharma S.p.A., a leading Italian firm in the field of osteoarticular and bone metabolism diseases.
About EcoVadis
EcoVadis is the world’s largest provider of business sustainability ratings, evaluating companies’ environmental, social, and ethical performance. Its platform helps businesses improve their sustainability practices and reduce risks in their supply chains.
Contact:
Vanessa Morales
EffRx Media
For more information about EffRx Pharmaceuticals and its commitment to sustainability, visit our website or contact our media.
